Please ensure Javascript is enabled for purposes of website accessibility

1 Green Flag for Axsome Therapeutics

By Taylor Carmichael - Mar 11, 2021 at 9:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The upstart biotech is filing two new drug applications in 2021, and has several more on the way.

Axsome Therapeutics (AXSM 6.11%) is approaching that important day in the life of a biotech when it shifts from unprofitable company to one that is marketing pharmaceuticals to the public. This specialist in drugs for the central nervous system is applying for two new drug applications with the Food and Drug Administration in 2021, and has two additional drugs just a year or two away from market. In this video clip from Motley Fool Live, recorded March 5, Corinne Cardina, bureau chief of healthcare and cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss Axsome.

Corinne Cardina: Let's talk about Axsome Therapeutics. What does this company have and what are briefly a green flag and red flag or yellow flag, any flags.

Taylor Carmichael: OK. Axsome Therapeutics is a company in the central nervous system space. If you have a lot of cancer stocks and you're like, I need to diversify, Axsome is a wonderful company. Thirty years ago, 40 years ago, we had a wave of depression drugs. We had Prozac, we had Zoloft and just a lot of depression drugs. Depression is a huge worldwide market. But we haven't had any new discoveries in a while and what Axsome has done, they've taken Wellbutrin, which is I think it was a GlaxoSmithKline (GSK 0.51%) drug. They've discovered that if you mix it with cough syrup, that it makes a more powerful drug. And so they reduced the dosage. Both of these drugs are off-patent now. They reduced the dosage of Wellbutrin, reduced dosage of cough syrup, figured out a way to make it safe, lowered the dosage and it's more effective than the original antidepressant. They've had this amazing run that they had two years ago from a micro cap all the way to about a $2 billion market cap valuation. Last year I think it was down slightly. They don't have any drugs on the market yet, but they're about to have a bunch. They have many drugs in phase 3 trials and they are out of phase 3 trials. They're going to have, I think, if I remember right, two approvals this year, might be one or two, I can't remember exactly.

Cardina: Right. The yellow flag for basically both of these, Nano-X and Axsome Therapeutics is execution risks. It's the biggest risk with any biotech company that hasn't sold anything on the market before.

Carmichael: Right.

Cardina: They're going to have to prove that they know how to commercialize. For some of these companies, they may partner with companies that have experience to get that. Others, they're going to be going at it alone. Definitely pay attention to how they debut on the market with these things.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
AXSM
$40.64 (6.11%) $2.34
GSK Stock Quote
GSK
GSK
$43.75 (0.51%) $0.22
Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
NNOX
$10.87 (-3.81%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.